Evidence map›Paper›PMID 31269226›Full record

ArticleMuscle & nerve2019

Validation of the triple timed up-and-go test in Lambert-Eaton myasthenia.

Shruti M Raja, Donald B Sanders, Vern C Juel, Yadollah Harati, A Gordon Smith, Robert Pascuzzi, David P Richman, Angie Wu, Kathy L Aleš, Laura R Jacobus and 3 more

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Muscle & nerve, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shruti M RajaDepartment of Neurology, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0003-0216-1564
Donald B SandersDepartment of Neurology, Duke University Medical Center, Durham, North Carolina.
Vern C JuelDepartment of Neurology, Duke University Medical Center, Durham, North Carolina.
Yadollah HaratiDepartment of Neurology, Baylor College of Medicine, Houston, Texas.
A Gordon SmithDepartment of Neurology, University of Utah School of Medicine, Salt Lake City, Utah.
Robert PascuzziDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana.
David P RichmanDepartment of Neurology, University of California Davis Medical Center, Sacramento, California.
Angie WuCenter for Predictive Modeling, Duke Clinical Research Institute, Durham, North Carolina.
Kathy L AlešJacobus Pharmaceutical Company, Princeton, New Jersey.
Laura R JacobusJacobus Pharmaceutical Company, Princeton, New Jersey.
David P JacobusJacobus Pharmaceutical Company, Princeton, New Jersey.
Jeffrey T GuptillDepartment of Neurology, Duke University Medical Center, Durham, North Carolina.
DAPPER Study Team

Funding

Immunological biomarker studies in myasthenia gravisK23NS085049 · NINDS · DUKE UNIVERSITY · PI GUPTILL, JEFFREY T · 2014 to 2018
$924k
NINDS NIH HHS K23 NS085049
6 · The paper itself

Abstract

introductionThere are no validated, practical, and quantitative measures of disease severity in Lambert-Eaton myasthenia (LEM).

methodsData from the Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (DAPPER) trial were analyzed to assess triple timed up-and-go (3TUG) reproducibility and relationships between 3TUG times and other measures of LEM severity.

resultsThe coverage probability technique showed ≥0.90 probability for an acceptable 3TUG difference of ≤0.2, indicating that it is reproducible in LEM patients. The correlation between 3TUG times and lower extremity function scores was significant in subjects who continued and in those who were withdrawn from 3,4-diaminopyridine free base. Worsening patient-reported Weakness Self-Assessment Scale and Investigator Assessment of Treatment Effect scores corresponded with prolongation of 3TUG times. DISCUSSION: The 3TUG is reproducible, demonstrates construct validity for assessment of lower extremity function in LEM patients, and correlates with changes in patient and physician assessments. These findings, along with prior reliability studies, indicate 3TUG is a valid measure of disease severity in LEM.

Indexed as

HumansLambert-Eaton Myasthenic SyndromeLower ExtremityMass ScreeningMuscle WeaknessPotassium Channel BlockersReproducibility of ResultsSeverity of Illness IndexPotassium Channel BlockersLambert-Eaton myastheniaLambert-Eaton myasthenic syndromeLambert-Eaton syndromeoutcome measurestimed up-and-go testvalidation

Identifiers

PMID31269226
PMCPMC7357813

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.